Patent · US Active

Methods and compositions comprising a KRasG12C inhibitor and a VEGF inhibitor for treating solid tumors

US12016862B2 · kind B2 · utility

1Cited by

1References

19Claims

0Family size

Assignee

Genentech, Inc. · US

Inventors

Marie Evangelista · San Francisco, US
Mark Merchant · South San Francisco, US
Jennifer Lee Schutzman · Belmont, US
Ting-Kun Mark Lin · Mill Valley, US
Stephanie Royer Joo · San Diego, US
Sandhya Vinayak Mandlekar · Foster City, US
Stuart Lutzker · Walnut Creek, US

Key dates

Filing date	Nov 11, 2021
Grant date	Jun 25, 2024
Priority date	—
Expiry date	Aug 22, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/545
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.